Photopheresis for early skin lymphoma in adults
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+) and weigh under 40 kg, with usable veins for an IV
- You have confirmed mycosis fungoides (skin biopsy that matches the diagnosis) and stage IA, IB, or IIA with measurable skin lesions
- You’re not currently on any other investigational (trial) drug or device, and you can follow study rules
- If you’re on certain skin or lymphoma medicines, you can safely stop them for the required “washout” time before starting
- Your disease is not controlled despite at least one standard treatment for early stages (like topical steroids, bexarotene, PUVA/UVB, or methotrexate)
- You can avoid sunbathing/phototherapy/tanning beds during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
This Phase 3 study tests a low-dose skin radiation treatment (electron beam) to help eradicate the harmful cancer cells in early-stage mycosis fungoides. It may be an option if you have stage IB or IIA disease and can safely undergo the required light/radiation preparation steps.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests whether ultra low-dose radiation can control specific skin lesions from mycosis fungoides (a type of lymphoma that affects the skin). It may help shrink or control targeted spots while using a lower radiation amount.
This early-phase study tests a spray solution (APR-TD011®) for people with early-stage mycosis fungoides and looks at how the bacteria on the skin change before and after treatment. It may help researchers understand whether the spray improves the skin environment that can affect this lymphoma.
This trial tests a cream applied to the skin that may help control early-stage mycosis fungoides, a type of skin lymphoma. It aims to see if the cream can reduce symptoms and slow disease progression without the need for stronger treatments.
Hear when a new Cutaneous T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.